GLP‑1 weight‑loss drugs Wegovy and Mounjaro face yo‑yo effect and price gaps

New GLP‑1 medications such as Wegovy (semaglutide) and Mounjaro (tirzepatide) have been hailed as breakthroughs for obesity, helping many patients lose significant weight by reducing appetite. However, research from Brazil indicates that once treatment stops, a substantial portion of the lost weight and related health markers tend to return, creating a potential new “yo‑yo” cycle where patients repeatedly start and stop therapy.

In the United Kingdom, the cost of an 18‑month course varies dramatically between pharmacies. The cheapest online price for a full Mounjaro regimen is about £4,656, while some providers charge over £8,000, a premium of more than £3,400. Wegovy shows similar variation, with a spread of roughly £3,700. Consumers can save thousands by comparing prices and using tools that track pharmacy charges, especially as competition intensifies ahead of the launch of a new oral weight‑loss pill by Eli Lilly.